ADMA Biologics announced third quarter 2025 financial results today, raised full-year 2025 revenue guidance, and reported FDA lot release of first yield-enhanced production batches expected to drive margin expansion starting in Q4 2025.
https://finviz.com/quote.ashx?t=ADMA&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.